Market Overview

Evercore Group Feels More Confident In Applied Micro Circuits


In a report published Wednesday, Evercore Group analyst Michael Lucarelli reiterated an Overweight rating and $15.00 price target on Applied Micro Circuits (NASDAQ: AMCC).

In the report, Evercore Group noted, “We are more confident in X-Gene's prospects after Cavium's ThunderX announcement reinforced a key pillar to our thesis: X-Gene's time to market advantage.

"ThunderX will likely not be in servers until 2H15 at which point X-Gene 1 will have been shipping ~1.5 years and XGene 2 for ~6 months. This comes on the heels of AMD confirming the necessity of a custom core (another pillar) when they announced in early May that they will bring a custom SoC (K12) to market in 2016. As such, the next 12-18 months will be critical for X-Gene to garner design wins and make significant inroads into the ARM server market.

"With purchase orders in hand across a spectrum of markets (OEM, cloud, HPC, and networking) and meaningful revenues just a few quarters away, we think Applied Micro (APM) is on its way. Reiterate OW and $15PT.”

Applied Micro Circuits closed on Tuesday at $8.98.

Latest Ratings for AMCC

Nov 2016DowngradesStrong BuyMarket Perform
Nov 2016DowngradesBuyHold
Sep 2016Initiates Coverage onNeutral

View More Analyst Ratings for AMCC
View the Latest Analyst Ratings

Posted-In: Evercore Group Michael LucarelliAnalyst Color Reiteration Analyst Ratings


Related Articles (AMCC)

View Comments and Join the Discussion!

Latest Ratings

ELMDDougherty & Co.Initiates Coverage On12.0
MRNSCantor FitzgeraldAssumes7.0
MNRLCapital One FinancialInitiates Coverage On23.0
SONVertical GroupUpgrades
UNPMorgan StanleyMaintains136.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Advaxis Reports Preclinical Study of LM-LLO Immunotherapy Showed Tumor Eradication

Benzinga's Top Upgrades